Axim Biotechnologies Inc (OTCMKTS:AXIM) Gets New U.S. Patent …

Axim Biotechnologies Inc (OTCMKTS:AXIM) reported that the USPTO has issued a Notice of Allowance for a patent that claims the application of an ophthalmic solution comprising CBDs for the treatment of symptomatic relief of conjunctival inflammation and glaucoma. A Notice of Allowance is given after the USPTO makes a decision that a patent can be given from AXIM’s patent application, filed in December 2015.

The details

Axim reported on March 21, 2017 that it kept the services of Ora®, Inc., an international Contract Research Organization, to perform the firm’s product development in dry eye syndrome and glaucoma using CBD-based therapeutics through its AX-1606 and AX-1603 clinical plans.

George E. Anastassov, MD, DDS, the CEO of Axim, reported that as they move forward in their product advancement and clinical studies for dry eye and glaucoma, this patent permitted by

... read more at: